Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

FDA Approves First Biosimilar for Treating Breast and Stomach Cancers

Jaime Rosenberg
Trastuzumab-dkst is the first biosimilar approved in the US for treating breast cancer or stomach cancer and the second biosimilar approved in the US for the treatment of cancer.
 
The FDA has approved the first biosimilar for the treatment of certain breast and stomach cancers, according to a press release from the administration.

Mylan GmbH’s trastuzumab-dkst (Ogivri) has been approved as a biosimilar to trastuzumab (Herceptin) for patients with breast or metastatic stomach cancer whose tumors overexpress the HER2 gene.

“The FDA continues to grow the number of biosimilar approvals, helping to promote competition that can lower health care costs. This is especially important when it comes to diseases like cancer, that have a high cost burden for patients,” said FDA Commissioner Scott Gottlieb, MD, in the statement. “We’re committed to taking new policy steps to advance our biosimilar pathway and promote more competition for biological drugs.”

According to the FDA, the approval of trastuzumab-dkst comes after a review of evidence that included:
  • Extensive structural and functional characterization
  • Animal study data
  • Human pharmacokinetic and pharmacodynamics data
  • Clinical immunogenicity data
  • Other clinical safety and effectiveness data that demonstrates trastuzumab-dkst is biosimilar to trastuzumab.
Common side effects of trastuzumab-dkst for the treatment of HER2+ breast cancer include headache, diarrhea, nausea, congestive heart failure, insomnia, and infection. Common side effects of the biosimilar for the treatment of HER2+ metastatic stomach cancer include neutropenia, stomatitis, low levels of blood platelets, and anemia.

Like trastuzumab, the labeling for trastuzumab-dkst includes a boxed warning to advise healthcare professionals and patients about the increased risk for heart disease, infusion reactions, lung damage, and harm to a developing fetus.

Trastuzumab-dkst is the first biosimilar approved in the US for treating breast cancer or stomach cancer and the second biosimilar approved in the US for the treatment of cancer.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!